Cargando…

Endotype-driven treatment in chronic upper airway diseases

Rhinitis and rhinosinusitis are the two major clinical entities of chronic upper airway disease. Chronic rhinosinusitis (CRS) and allergic rhinitis (AR) affect respectively up to 10 and 30% of the total population, hence being associated with an important socio-economic burden. Different phenotypes...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Greve, Glynnis, Hellings, Peter W., Fokkens, Wytske J., Pugin, Benoit, Steelant, Brecht, Seys, Sven F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5506670/ https://www.ncbi.nlm.nih.gov/pubmed/28706720 http://dx.doi.org/10.1186/s13601-017-0157-8

Ejemplares similares

Visual analogue scale for sino-nasal symptoms severity correlates with sino-nasal outcome test 22: paving the way for a simple outcome tool of CRS burden
por: Doulaptsi, Maria, et al.
Publicado: (2018)

Lacticaseibacillus casei AMBR2 Restores Airway Epithelial Integrity in Chronic Rhinosinusitis With Nasal Polyps
por: Martens, Katleen, et al.
Publicado: (2021)

Erratum: Lacticaseibacillus casei AMBR2 Restores Airway Epithelial Integrity in Chronic Rhinosinusitis With Nasal Polyps
por: Martens, Katleen, et al.
Publicado: (2021)

A TRiP Through the Roles of Transient Receptor Potential Cation Channels in Type 2 Upper Airway Inflammation
por: Backaert, Wout, et al.
Publicado: (2021)

Mometasone furoate and fluticasone furoate are equally effective in restoring nasal epithelial barrier dysfunction in allergic rhinitis
por: Doulaptsi, Maria, et al.
Publicado: (2021)

Prevalence and triggers of self-reported nasal hyperreactivity in adults with asthma
por: Feijen, Jef, et al.
Publicado: (2020)

Epithelial barriers in allergy and asthma
por: Hellings, Peter W., et al.
Publicado: (2020)

Calu-3 epithelial cells exhibit different immune and epithelial barrier responses from freshly isolated primary nasal epithelial cells in vitro
por: Martens, Katleen, et al.
Publicado: (2018)

Endotyping of non-allergic, allergic and mixed rhinitis patients using a broad panel of biomarkers in nasal secretions
por: Segboer, Christine L., et al.
Publicado: (2018)

Anterior Nares Diversity and Pathobionts Represent Sinus Microbiome in Chronic Rhinosinusitis
por: De Boeck, Ilke, et al.
Publicado: (2019)

Capsaicin for Rhinitis
por: Fokkens, Wytske, et al.
Publicado: (2016)

Acute and chronic rhinosinusitis and allergic rhinitis in relation to comorbidity, ethnicity and environment
por: Hoffmans, Ruth, et al.
Publicado: (2018)

Monoclonal antibody or aspirin desensitization in NSAID-exacerbated respiratory disease (N-ERD)?
por: Van Broeck, Dorien, et al.
Publicado: (2023)

European Summit on the Prevention and Self-Management of Chronic Respiratory Diseases: report of the European Union Parliament Summit (29 March 2017)
por: Hellings, Peter W., et al.
Publicado: (2017)

Inflammatory Endotype-Associated Airway Resistome in Chronic Obstructive Pulmonary Disease
por: Yi, Xinzhu, et al.
Publicado: (2022)

Taste Receptors: The Gatekeepers of the Airway Epithelium
por: Martens, Katleen, et al.
Publicado: (2021)

Airway Basal Cells, Protectors of Epithelial Walls in Health and Respiratory Diseases
por: Ruysseveldt, Emma, et al.
Publicado: (2021)

A new allergic rhinitis therapy (MP29-02*) provides effective and rapid symptom relief for patients who suffer most from the bothersome symptoms of nasal congestion or ocular itch
por: Fokkens, Wytske, et al.
Publicado: (2015)

Identification of gaps in the current allergic rhinitis guidelines and how these can be filled
por: Bousquet, Jean, et al.
Publicado: (2015)

Short and long-term safety of MP29-02*: a new therapy for the treatment of allergic rhinitis
por: Price, David, et al.
Publicado: (2013)

Examining the impact of multilevel upper airway surgery on the obstructive sleep apnoea endotypes and their utility in predicting surgical outcomes
por: Wong, Ai‐Ming, et al.
Publicado: (2022)

Quality of life and use of medication in chronic allergic and non-allergic rhinitis patients
por: Segboer, Christine, et al.
Publicado: (2013)

A new allergic rhinitis therapy (MP29-02*) provides nasal and ocular symptom relief days faster than current firstline monotherapies
por: Hellings, Peter, et al.
Publicado: (2015)

A new intranasal therapy (MP29-02*) is more effective than current firstline therapy regardless of season, symptom or severity.
por: Bachert, Claus, et al.
Publicado: (2015)

MP29-02*’s advanced delivery system contributes to its efficacy in patients with moderate/severe seasonal allergic rhinitis
por: Scadding, Glenis, et al.
Publicado: (2015)

Brain activation after nasal histamine provocation in house dust mite allergic rhinitis patients
por: Callebaut, Ina, et al.
Publicado: (2020)

EUFOREA consensus on biologics for CRSwNP with or without asthma
por: Fokkens, Wytske J., et al.
Publicado: (2019)

Advances in the Knowledge of the Underlying Airway Remodeling Mechanisms in Chronic Rhinosinusitis Based on the Endotypes: A Review
por: Lee, Kijeong, et al.
Publicado: (2021)

Association between outdoor air pollution and chronic rhinosinusitis patient reported outcomes
por: Peeters, S., et al.
Publicado: (2022)

Chronic rhinosinusitis with nasal polyps in the elderly
por: Cornet, Marjolein, et al.
Publicado: (2013)

Precision Medicine in Chronic Rhinosinusitis with Nasal Polyps
por: Avdeeva, Klementina, et al.
Publicado: (2018)

Inflammatory Endotypes and Microbial Associations in Chronic Rhinosinusitis
por: Hoggard, Michael, et al.
Publicado: (2018)

Does the Difference in Microbial Patterns in the Airways Induce Distinct Endotypes of Asthma?
por: Cho, Young Joo
Publicado: (2020)

Allergic fungal airways disease (AFAD): an under-recognised asthma endotype
por: Pashley, Catherine H., et al.
Publicado: (2021)

A new therapy (MP29-02*) effectively targets the entire seasonal allergic rhinitis symptom complex
por: Price, David, et al.
Publicado: (2013)

A new therapy (MP29-02*) effectively treats patients with seasonal allergic rhinitis who suffer most from the bothersome nasal symptom of congestion
por: Bachert, Claus, et al.
Publicado: (2013)

A new therapy (MP29-02*) effectively controls nasal symptoms of seasonal allergic rhinitis irrespective of severity
por: Scadding, Glenis, et al.
Publicado: (2013)

A new therapy (MP29-02*) provides effective relief from all individual nasal and ocular symptoms of seasonal allergic rhinitis
por: Hellings, Peter, et al.
Publicado: (2013)

A new efficacy parameter (complete/near complete symptom relief) in allergic rhinitis management: results with a new therapy MP29-02*
por: Bousquet, Jean, et al.
Publicado: (2013)

Carbon loading in airway macrophages to traffic-derived particulate matter air pollution
por: Bai, Yang, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_feajilouucd6phdgn92klcba5k